Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05926414 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorCompletion date: Jun 30, 2025 to Dec 31, 2025v7
MinorPrimary completion date changed from estimate of Jan 31, 2025 to Jan 17, 2025v6
MinorTrial status: Recruiting to Active, Not RecruitingPrimary completion date: Dec 31, 2024 to Jan 31, 2025 · Site details revisedv5Show 2 more changesShow less
Primary completion date: Dec 31, 2024 to Jan 31, 2025
Site details revised
MinorRe-verified, no change to tracked fieldsv4
NotablePrimary endpoint revisedPrimary completion date: Dec 2024 to Dec 31, 2024 · Completion date: Jun 2025 to Jun 30, 2025 · Secondary endpoints expanded, about 65 wordsv3Show 3 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingEnrollment target: 10000 to 15000 · Study sites: 0 to 1 · Start date changed from estimate of Jul 2023 to Sep 21, 2023 · 4 morev2Show 7 more changesShow less
Enrollment target: 10000 to 15000
Study sites: 0 to 1
Start date changed from estimate of Jul 2023 to Sep 21, 2023
Interventions: Enavogliflozin (Drug) to Enavogliflozin (Drug), Enavogliflozin (Drug)
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This observation study is designed as a prospective, multi-organ observation study to confirm the blood sugar control effect and safety of ENVLO tablet or Envlomet SR Tablet administration for 24 weeks in patients with type 2 diabetes who are scheduled to administer ENVLO tablet in the actual treatment environment.